scholarly journals Foot-and-Mouth Disease Virus Lacking the VP1 G-H Loop: The Mutant Spectrum Uncovers Interactions among Antigenic Sites for Fitness Gain

Virology ◽  
2001 ◽  
Vol 288 (2) ◽  
pp. 192-202 ◽  
Author(s):  
Eric Baranowski ◽  
Carmen M. Ruiz-Jarabo ◽  
Filip Lim ◽  
Esteban Domingo
Keyword(s):  
Disease Virus ◽  
Foot And Mouth Disease ◽  
Mouth Disease ◽  
Antigenic Sites ◽  
Mouth Disease Virus ◽  
Foot And Mouth ◽  
Mutant Spectrum

scholarly journals Predicting antigenic sites on the foot-and-mouth disease virus capsid of the South African Territories types using virus neutralization data

2011 ◽  
Vol 92 (10) ◽  
pp. 2297-2309 ◽  
Author(s):  
F. F. Maree ◽  
B. Blignaut ◽  
J. J. Esterhuysen ◽  
T. A. P. de Beer ◽  
J. Theron ◽  
...  
Keyword(s):  
South African ◽  
Disease Virus ◽  
Foot And Mouth Disease ◽  
Mouth Disease ◽  
Sub Saharan Africa ◽  
Antigenic Sites ◽  
Mouth Disease Virus ◽  
Virus Serotype ◽  
Antigenic Properties ◽  
Foot And Mouth

Foot-and-mouth disease virus (FMDV) outer capsid proteins 1B, 1C and 1D contribute to the virus serotype distribution and antigenic variants that exist within each of the seven serotypes. This study presents phylogenetic, genetic and antigenic analyses of South African Territories (SAT) serotypes prevalent in sub-Saharan Africa. Here, we show that the high levels of genetic diversity in the P1-coding region within the SAT serotypes are reflected in the antigenic properties of these viruses and therefore have implications for the selection of vaccine strains that would provide the best vaccine match against emerging viruses. Interestingly, although SAT1 and SAT2 viruses displayed similar genetic variation within each serotype (32 % variable amino acids), antigenic disparity, as measured by r1-values, was less pronounced for SAT1 viruses compared with SAT2 viruses within our dataset, emphasizing the high antigenic variation within the SAT2 serotype. Furthermore, we combined amino acid variation and the r1-values with crystallographic structural data and were able to predict areas on the surface of the FMD virion as antigenically relevant. These sites were mostly consistent with antigenic sites previously determined for types A, O and C using mAbs and escape mutant studies. Our methodology offers a quick alternative to determine antigenic relevant sites for FMDV field strains.

scholarly journals Analysis of neutralizing antigenic sites on the surface of type A12 foot-and-mouth disease virus.

1989 ◽  
Vol 63 (5) ◽  
pp. 2143-2151 ◽  
Author(s):  
B Baxt ◽  
V Vakharia ◽  
D M Moore ◽  
A J Franke ◽  
D O Morgan
Keyword(s):  
Disease Virus ◽  
Foot And Mouth Disease ◽  
Mouth Disease ◽  
Antigenic Sites ◽  
Mouth Disease Virus ◽  
Foot And Mouth

scholarly journals Mapping of antigenic sites of foot-and-mouth disease virus serotype Asia 1 and relationships with sites described in other serotypes

2013 ◽  
Vol 94 (3) ◽  
pp. 559-569 ◽  
Author(s):  
Santina Grazioli ◽  
Francesca Fallacara ◽  
Emiliana Brocchi
Keyword(s):  
Disease Virus ◽  
Foot And Mouth Disease ◽  
Mouth Disease ◽  
Antigenic Structure ◽  
Antigenic Sites ◽  
Fmdv Serotype ◽  
Fmdv Serotypes ◽  
Mouth Disease Virus ◽  
Foot And Mouth ◽  
Serotype Asia 1

Knowledge of the antigenic structure of foot-and-mouth disease virus (FMDV) has relevance in the development of diagnostic assays, in the evaluation of the antigenic variability and in the selection of appropriate vaccine strains. Antigenic sites have been investigated only in FMDVs of serotypes O, A and C, while it would be valuable to extend studies also to other serotypes. This paper reports the identification of antigenic sites involved in virus neutralization in the FMDV serotype Asia 1 by using a new panel of mAbs and their relation with sites described in other serotypes is discussed. Out of 24 mAbs raised against the FMDV serotype Asia 1, 10 neutralize viral infectivity and were used to select FMDV mutants resistant to neutralization. On the basis of their reactivity profile with virus mutants, the 10 neutralizing mAbs were clustered in four groups corresponding to four independent antigenic sites. By comparing the amino acid sequence of the parental virus and of virus mutants, the amino acids crucial for the four sites were mapped at the following positions: VP1 140–142, VP2 67–79, VP3 58/59 and VP3 218. Three of the four neutralizing sites identified and mapped on FMDV serotype Asia 1 correspond structurally and functionally to analogous sites described in FMDV serotypes O, A and C, enforcing the evidence that these are dominant antigenic sites in the FMDV structure. The fourth site, located at the C terminus of VP3, is a new independent site, described for the first time in FMDV.

scholarly journals Antigenic sites on foot-and-mouth disease virus type A10.

1988 ◽  
Vol 62 (8) ◽  
pp. 2782-2789 ◽  
Author(s):  
A A Thomas ◽  
R J Woortmeijer ◽  
W Puijk ◽  
S J Barteling
Keyword(s):  
Disease Virus ◽  
Virus Type ◽  
Foot And Mouth Disease ◽  
Mouth Disease ◽  
Antigenic Sites ◽  
Mouth Disease Virus ◽  
Foot And Mouth ◽  
Disease Virus Type

scholarly journals Antigenic sites of foot-and-mouth disease virus (FMDV): an analysis of the specificities of anti-FMDV antibodies after vaccination of naturally susceptible host species

2002 ◽  
Vol 83 (4) ◽  
pp. 775-782 ◽  
Author(s):  
N. Aggarwal ◽  
P. V. Barnett
Keyword(s):  
Immune Response ◽  
Disease Virus ◽  
Foot And Mouth Disease ◽  
Mouth Disease ◽  
Protective Immune Response ◽  
Susceptible Host ◽  
Ruminant Species ◽  
Antigenic Sites ◽  
Mouth Disease Virus ◽  
Foot And Mouth

Of the known neutralizing antigenic sites of foot-and-mouth disease virus (FMDV), site 1 or A, formed in part by the G–H loop of VP1, has historically been considered immunodominant because of evidence implicating its importance in the induction of a protective immune response. However, no systematic study has been done to determine the relative importance of the various specificities of antibodies against the known neutralizing antigenic sites of FMDV in the polyclonal immune response of a natural host after vaccination. In this report, we have adopted a monoclonal antibody-based competition ELISA and used antibodies specific to sites 1, 2 and 3 to provide some insight into this issue. Following vaccination of the three main target species, cattle, pigs and sheep, with an O1 serotype strain, results indicate that none of these three antigenic sites can be considered immunodominant in a polyclonal serum. Interestingly, pigs did not respond to epitopes on the carboxy terminus end of VP1 as efficiently as the ruminant species. In addition to the known sites, other as yet undefined sites might also be important in the induction of a protective immune response. Possible implications for the design of new vaccine strategies for foot-and-mouth disease are discussed.

scholarly journals Foot-and-mouth disease virus epitope dominance in the antibody response of vaccinated animals

2012 ◽  
Vol 93 (3) ◽  
pp. 488-493 ◽  
Author(s):  
M. Mahapatra ◽  
P. Hamblin ◽  
D. J. Paton
Keyword(s):  
Disease Virus ◽  
Antigenic Site ◽  
Foot And Mouth Disease ◽  
Mouth Disease ◽  
Escape Mutant ◽  
Target Species ◽  
Serotype O ◽  
Antigenic Sites ◽  
Mouth Disease Virus ◽  
Foot And Mouth

Five neutralizing antigenic sites have been identified on the surface of serotype O foot-and-mouth disease virus (FMDV). A set of mAb neutralization-escape mutant viruses was used for the first time to evaluate the relative use of known binding sites by polyclonal antibodies from three target species: cattle, sheep and pigs. Antibodies to all five neutralizing antigenic sites were detected in all three species, with most antibodies directed against antigenic site 2, followed by antigenic site 1. In 76 % of cattle, 65 % of sheep and 58 % of pigs, most antibodies were directed against site 2. Antibodies specific to antigenic sites 3, 4 and 5 were found to be minor constituents in the sera of each of the target species. This implies that antigenic site 2 is a dominant neutralization immunogenic site in serotype O FMDV and may therefore be a good candidate for designing novel vaccines.

Sign in / Sign up

Export Citation Format

Share Document